BioMedNewsBreaks

WednesdaySep 22, 2021 2:26 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) to Present at Wall Street Reporter’s ‘Next Super Stock’ Livestream Conference

RYAH Group (CSE: RYAH) today announced that its Chief Executive Officer Gregory Wagner will be presenting at Wall Street Reporter's "Next Super Stock" livestream conference on Thursday, Sept. 23, 2021. The online event is expected to give the investment community and existing shareholders an opportunity to interact in real time with Wagner and learn about the company and its operations. Wagner’s presentation is scheduled to begin at 1:00 ET on the day of the conference, during which he will highlight RYAH’s experience and mission, and, time permitting, open the floor for questions. Interested parties should visit https://ibn.fm/K0MtA to ensure access…

Continue Reading

WednesdaySep 22, 2021 2:08 pm

BioMedNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Submission of IND Application for Eating Disorders Clinical Trial

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has submitted an Investigational New Drug ("IND") application to the U.S. Food and Drug Administration ("FDA"). The clinical trial is designed to evaluate the efficacy of TRYP’s clinical candidate, TRP-8802, for the treatment of patients with eating disorders. TRYP is working with Jennifer Miller, MD, from the University of Florida, to conduct the trial as well as evaluate its oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. The IND application outlines specifics in regard to the safety of…

Continue Reading

WednesdaySep 22, 2021 12:30 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Healthcare Small Cap Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild to moderate obstructive sleep apnea (“OSA”), today announced that its chairman and CEO Kirk Huntsman and CFO Brad Amman will be presenting at the online Benzinga Healthcare Small Cap Conference at 2:20 pm ET on Wednesday, Sept. 29, 2021. The event is scheduled to take place from Sept. 29-30, 2021. Investors interested in joining the Vivos presentation should visit https://ibn.fm/JFY3h to register for a free spectator pass. A replay of the presentation will be available for view…

Continue Reading

FridaySep 17, 2021 3:08 pm

BioMedNewsBreaks – RYAH Group Inc. (CSE: RYAH) Leveraging IoT Devices, AI Analytics to Provide Innovative Plant-Based Treatments

RYAH Group (CSE: RYAH), a connected device and big data and technology company, recently released a report outlining cannabis treatment options to address symptoms and conditions associated with HIV and AIDS. The report is based on information compiled by the RYAH Data Ecosystem, which enabled patients to submit data outlining symptoms they addressed with the use of cannabis, in addition to detailing specific cannabis strains used to treat those conditions. A recent article reads, “The ground-breaking report is part of RYAH’s data-driven mission to provide innovative plant-based medical treatments that leverage the use of IoT (Internet of Things) dose-measuring devices…

Continue Reading

FridaySep 17, 2021 12:33 pm

BioMedNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Names World-Renowned Thought Leader as Advisory Board Member

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing noninvasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, announced that Dr. Osama Hamdy, MD, PhD, has joined its advisory board. Hamdy will act as a consultant and will provide invaluable input regarding key opinion leader studies in both the diabetes and metabolic health fields using Nemaura’s glucose monitoring technology. An acclaimed endocrinologist, Hamdy is medical director of the Obesity Clinic Program at the Joslin Diabetes Center; he is also an associate professor of medicine at Harvard Medical School. He has built a stellar reputation as…

Continue Reading

FridaySep 17, 2021 12:09 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM), BayMedica Slated to Participate in Tribe Public Webinar

InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has announced that its CEO Eric A. Adams will be a featured presenter at Tribe Public’s upcoming complimentary ZOOM presentation titled “Accelerating The Commercialization of Rare Cannabinoids.” The webinar is scheduled to begin on Sept. 21, 2021, at 11.30 a.m. ET. In addition to Adams, BayMedica Inc. cofounder Shane Johnson will also present during the event. Adams and Johnson’s presentation will be hosted by Tribe Public managing member John F. Heerdink Jr., who will field live questions and pass those on to the presenters. In…

Continue Reading

FridaySep 17, 2021 9:56 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Exec to Participate in Upcoming in Mental Health Virtual Conference

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, has announced that president and CEO Kelsey Ramsden will be participating in the Advances in Mental Health Virtual Conference. The one-day conference, presented by Maxim Group LLC and hosted by M-Vest, is scheduled for Sept. 22, 2021. Ramsden will be a panel member in two separate sessions held during the virtual event. The panels, which are part of the “Disruptors in the Mental Health Space” series, are titled “The Second Generation – Beyond Psilocybin and MDMA”and “Delivery, Manufacturing and Technology” and will…

Continue Reading

ThursdaySep 16, 2021 9:35 am

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) Announces Partnership Digital Therapeutics Alliance

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH), a leader in advanced proprietary technology and research for psychedelics, is joining the Digital Therapeutics Alliance. A nonprofit association of industry leaders, the alliance is dedicated to driving awareness and adoption of digital therapies. MINDCURE announced that, as part of the alliance, the company is committed to providing value and reimbursement, policy and regulation, and awareness to educate the broader health-care industry about the benefits of including new technologies in current treatment regimes. Collaboration with the alliance is a strategic move as MINDCURE works to position iSTRYM, its proprietary software application, as…

Continue Reading

TuesdaySep 14, 2021 2:55 pm

BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Leveraging Partnerships to Save Patients’ Lives, Broaden Product Pipeline

AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, recently announced a cooperation agreement with Roche Pharmaceuticals China, a subsidiary of Roche Holdings AG, to explore novel medical solutions. Under the agreement, “both parties plan to utilize AnPac Bio’s Cancer Differentiation Analysis (‘CDA’) cancer detection technology and Roche’s FoundationOne CDx to create a solution that customers with a high cancer risk level as assessed by CDA and later diagnosed with cancer can receive a personalized CDx precision medical test for therapy selection. The parties aim to help benefit the general population while lowering costs…

Continue Reading

TuesdaySep 14, 2021 2:36 pm

BioMedNewsBreaks – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) Is Frontrunner in Support of Psychedelic-Assisted Therapy

Mind Cure Health (CSE: MCUR) (OTCQB: MCURF), a leader in advanced proprietary technology and research for psychedelics, is devoted to building access to safe, science- and evidence-backed psychedelic-assisted therapies globally. “The company has filed a provisional patent application for its pharmaceutical-grade synthetic ibogaine to be used in clinical research and anticipates developing that in conjunction with its software-as-a-service (‘SaaS’) platform iSTRYM,” reads a recent article. iSTRYM is designed to help physicians and patients manage psychiatric medications using smart “digital therapeutics” technology. On August 10, MCURF announced an agreement with Dr. Ken Weingardt to provide consulting services as a senior clinical…

Continue Reading